Navigation Links
Response to First Treatment May Predict Epilepsy's Course
Date:5/9/2012

By Serena Gordon
HealthDay Reporter

WEDNESDAY, May 9 (HealthDay News) -- The way someone responds to the first anti-seizure medication given after a diagnosis of epilepsy often predicts how well- controlled their seizures will be over time.

A new study found that about 50 percent of people became seizure-free after the first medication they took. By contrast, only 13 percent became seizure-free after the second drug was tried, and just 4 percent were seizure-free after a third drug was tried.

"The long-term treatment outcome is fairly constant, and thus predictable early on, in most people with epilepsy," said the study's lead author, Dr. Patrick Kwan, a professor of neurology at the University of Melbourne, in Australia. "Few patients become seizure-free after failure of the first two medications tried," he added.

Results of the study are published in the May 9 online issue of the journal Neurology.

Epilepsy is a seizure disorder. You generally have to have two or more unexplained seizures to be diagnosed with epilepsy, according to the Epilepsy Foundation. About 70 million people have epilepsy worldwide, according to background information in the study.

A number of medications are available to stop seizures, and these may be given alone or in combination. Brain surgery and other non-drug options are available for treating epilepsy.

The current study included nearly 1,100 people aged 9 to 93 who were newly diagnosed with epilepsy and prescribed one medication as their initial treatment. The median age of the study volunteers was 32 years, and they were followed for up to 26 years.

Sixty-eight percent were seizure-free at the final clinic visit. Sixty-two percent of those people were seizure-free on a single drug therapy. Study participants were considered seizure-free if they hadn't had a seizure in at least a year without any changes in their treatment.

The response
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. People with anxiety disorder less able to regulate response to negative emotions, study shows
2. ASCROs Response to NY Times Articles on Radiation Therapy Incidents
3. TV Shows Often Botch Proper Seizure Responses
4. Belief in a caring god improves response to medical treatment for depression
5. Aggressive response helped Chilean hospital improve H1N1 influenza outcomes
6. International Medical Corps Emergency Response Team on Standby as It Monitors Situation in Chile and Potential Tsunami Areas
7. Tips for Safe Charitable Giving in Response to Earthquakes in Chile and Haiti
8. NOW Foods Response to Fish Oil and PCB Concerns
9. Bodys Response to Foods Smell, Taste Could Be Diabetes Risk Factor
10. Protein in Breast Tumors May Predict Chemo Response
11. Merely seeing disease symptoms may promote aggressive immune response
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Response to First Treatment May Predict Epilepsy's Course
(Date:5/21/2013)... 2013 Standard advice for mattress shoppers ... else. However given industry’s less than exceptional satisfaction ratings ... the internet, Consumer Mattress Reports sets out to revise ... Best Mattress .” , This article addresses several components ... that may not be readily apparent to many shoppers. ...
(Date:5/21/2013)... 2013 DISCcert has served the training ... use 17 DISC applications at the July 25 & ... , The July 25 & 26th DISC certification in ... of applying DISC. The time-tested, proven support materials will ... DISC training materials ; worksheets, handouts, learning ...
(Date:5/21/2013)... 2013 Parker Waichman LLP, a national ... injured by defective medical devices, is addressing new research ... on May 15, 2013. The study found that magnetic ... that occur in patients with metal-on-metal hip implants even ... ) , “We’ve known for quite ...
(Date:5/21/2013)... France: The Orsiro stent, which is a novel ... demonstrated non-inferiority to the Xience Prime everolimus-eluting stent ... lumen loss at nine months in the results ... today. , The BIOFLOW-II substudy used intravascular ultrasound ... assess neointimal hyperplasia and stent apposition at nine ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Phoseon Technology ... at the 20th Annual IMI European Ink Jet ... proven market leader, Phoseon continues to invest in product ... the adoption of UV LED curing in printing applications. ... families on the market offering both air cooled and ...
Breaking Medicine News(10 mins):Health News:Choosing the Best Mattress Simplified in Consumer Mattress Reports’ Latest Article 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2
... International Liver Congress 2009, the 44th annual meeting of the ... Journalist registrations are being accepted for International Liver Congress 2009, ... , Press registration is free of charge for all holders ... The official EASL press conference will be held from 13.15 ...
... A failing heart makes a lot of a hormone needed ... but not enough of the enzyme needed to activate it, ... College of Georgia researchers found people in heart failure have ... pro-atrial natriuretic peptide, a hormone made by heart muscle cells ...
... WASHINGTON, March 31 Jeffrey Levi, Ph.D., ... today before the U.S. House Energy and Commerce Committee,s ... Care Work for American Families: Protecting the Public Health." ... investing in prevention, and the importance of incorporating public ...
... March 31 The not-for-profit LENA Foundation ... Biennial Meeting of the Society of Research in Child ... Colorado, four talks and one poster will be presented ... http://www.newscom.com/cgi-bin/prnh/20090210/LA69114 )"This year,s SRCD is a great opportunity ...
... 31 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS) ... Award" is a most coveted, prestigious award, and ... Science and Technological Development. Submitted with the award ... preliminary trial of their Ribavirin product, confirming its ...
... March 31 Five local organizations and,individuals committed ... cholesterol,in Hispanic communities were awarded 2009 Cheerios Angel ... Chosen from a winning pool of nominations, ... healthier lifestyles and provided excellent resources to help ...
Cached Medicine News:Health News:New tests provide new insight into why patients are in heart failure 2Health News:New tests provide new insight into why patients are in heart failure 3Health News:Trust for America's Health Testifies before Congress on Building Prevention into Health Reform 2Health News:Trust for America's Health Testifies before Congress on Building Prevention into Health Reform 3Health News:Trust for America's Health Testifies before Congress on Building Prevention into Health Reform 4Health News:Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation 2Health News:Five Research Studies at International SRCD Meeting in Denver Use Technology from Boulder Foundation 3Health News:Hard To Treat Diseases (HTDS) Best Technological Innovation Award 2009 2Health News:Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S. 2Health News:Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S. 3Health News:Cheerios(R) Angel de mi Corazon Awards $25,000 to Those Who Fight Heart Disease and High Cholesterol in Hispanic Communities Across the U.S. 4
(Date:5/21/2013)... and TARRYTOWN, N.Y. , May ... SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced ... published online the positive Phase 2a study results of ... is an investigational monoclonal antibody targeting the alpha subunit ... signaling of both IL-4 and IL-13, drivers of Th2 ...
(Date:5/21/2013)... UNION CITY, Calif. , May 21, 2013 /PRNewswire/ ... manufacturing point-of-care blood analysis systems, announced today that ... will present at the Stifel Annual Dental & Veterinary ... ET. The conference will be held at Le Parker ... . About Abaxis Abaxis develops, ...
(Date:5/21/2013)... May 21, 2013 Reportlinker.com announces ... available in its catalogue:   ... Scenario for Medical Devices in the US ...   Changing Regulatory and Reimbursement ... Market   Summary ...
Breaking Medicine Technology:Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4
... HIGHLIGHTS:2011 Results (all percentages are to ... reported sales increased 11% to $626 million. Q3 sales grew ... sales growing organically by 4% and 2%, respectively.  Recently completed ... exchange rates contributed an additional 5% to reported sales growth ...
... Botanic Pharmaceutical Inc. (NYSE AMEX: CBP ) ... distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ... recently hosted a technical exchange between 13 senior research ... and herbal medicine. China Botanic participated ...
Cached Medicine Technology:Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13China Botanic Hosts Technical Exchange for Industry Research Experts 2China Botanic Hosts Technical Exchange for Industry Research Experts 3
A gentle yet highly effective corneal rust ring remover with Alger brush of 1mm burr. Runs off 1 x AA battery, no switches, simply spin mandrel to operate....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings. Ophtho-burr handpiece only. Battery powered handpiece....
Katena ophthalmic burr for polishing pterygiums, includes one round diamond burr and has an storage case....
Medicine Products: